SUN’IY SHIRIN TA’M BERUVCHI ASPARTAMNING LABORATORIYA HAYVONLARI QONINING LIPID ALMASHINUVI KO‘RSATKICHLARIGA SURUNKALI TA’SIRI
Keywords:
: aspartam, sun’iy shirinlovchi, lipid almashinuvi, xolesterin, aterogenlik koeffitsienti, ZYuLP, ZPLP, trigliseridlar, laboratoriya hayvonlariAbstract
Mazkur tadqiqotda aspartamning (20 mg/kg•kun) laboratoriya hayvonlarida lipid almashinuviga 30 va 60 kunlik surunkali ta’siri o‘rganildi (Wistar kalamushlar, n=20). Qon zardobida umumiy xolesterin, trigliseridlar, ZYuLP, ZPLP aniqlanib, aterogenlik koeffitsienti hisoblandi. 30-kunda umumiy xolesterin 19,4% ga, trigliseridlar 16,1% ga va ZPLP 10,9% ga kamaydi (p<0,05). 60-kunda ZPLP 26,6% ga pasaydi, biroq ZYuLP darajasi 30,9% ga kamaydi (p<0,05). Aterogenlik koeffitsienti esa 38,5% ga oshdi (p<0,05).Natijalar aspartamning dastlab gipolipidemik, ammo keyinchalik proaterogen ta’sir ko‘rsatishini tasdiqlaydi. ZYuLP kamayishi va AK oshishi lipid profilining aterogen yo‘nalishda o‘zgarishini bildiradi hamda uzoq muddatli iste’molda kardiovaskulyar xavf ortishini ko‘rsatadi.
References
1. Swithers, S. E. (2013). Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. Trends in Endocrinology & Metabolism, 24(9), 431–441.
https://doi.org/10.1016/j.tem.2013.05.005
2. Suez, J., Korem, T., Zeevi, D., et al. (2014). Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature, 514(7521), 181–186.
https://doi.org/10.1038/nature13793
3. Mamazulunov, N. (2021). Inorganic phosphate and principles of fluorescence. Экономика и социум, (3-1 (82)), 167-169.
4. Palmnäs, M. S. A., Cowan, T. E., Bomhof, M. R., et al. (2014). Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat. PLOS ONE, 9(10), e109841.
https://doi.org/10.1371/journal.pone.0109841
5. Butchko, H. H., Stargel, W. W., Comer, C. P., et al. (2002). Aspartame: Review of safety. Regulatory Toxicology and Pharmacology, 35(2), S1–S93.
https://doi.org/10.1006/rtph.2002.1542
6. Юлдашев, Н., Мамазулунов, Н., & Хабибуллаев, С. Научное обозрение. Биологические науки. Научное обозрение, (2), 51-57.
7. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2018). 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143.
https://doi.org/10.1161/CIR.0000000000000625
8. Imamura, F., O’Connor, L., Ye, Z., et al. (2015). Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes. BMJ, 351, h3576.
https://doi.org/10.1136/bmj.h3576
9. Икрамова, М. М., Таджибоев, К. Т., & Мамазулунов, Н. Х. (2013). Определение активности аминотрансфераза в перфузате печени при экспериментальном токсическом гепатите. science and world, 42.
10. Koeth, R. A., Wang, Z., Levison, B. S., et al. (2013). Intestinal microbiota metabolism of L-carnitine promotes atherosclerosis. Nature Medicine, 19(5), 576–585.
https://doi.org/10.1038/nm.3145
11. Gordon, D. J., Probstfield, J. L., Garrison, R. J., et al. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Circulation, 79(1), 8–15.
https://doi.org/10.1161/01.CIR.79.1.8
12. Khabibullaev, S., Yuldashev, N., & Mamazulunov, N. (2023). Metabolic changes in the body as the result of long-term use of artificial sweetener-sodium cyclamate. Science and innovation, 2(D10), 64-70..
13. Tall, A. R. (2008). CETP inhibitors to increase HDL cholesterol levels. New England Journal of Medicine, 356(13), 1364–1366.
https://doi.org/10.1056/NEJMe078014
14. Magnuson, B. A., Burdock, G. A., Doull, J., et al. (2007). Aspartame: A safety evaluation based on current use levels. Critical Reviews in Toxicology, 37(8), 629–727.
